Philip Morris
Patents
Fields
- Type
- REPT, OTHER REPORT
- Site
- R37
- Master ID
- 1000229536/9811
Related Documents:- 1000229537-9544
- 1000229545-9550 Brief Synopsis
- 1000229551-9552 Introduction
- 1000229553-9555 Brief History of Cetus Financing
- 1000229556-9557
- 1000229558-9560 Special Note to Investors
- 1000229561-9563 Special Note Regarding Founder's Stock
- 1000229567-9569 Board of Directors
- 1000229575-9580 Achievements of Cetus People
- 1000229581-9599 Present Cetus Activities
- 1000229600-9616 Research Plan
- 1000229621-9656 Debenture Purchase Agreement
- 1000229657-9661 the Cetus Story
- 1000229663-9667 Cloning Business: It's Growing Fast It's Growing Fast
- 1000229668 World Roundup
- 1000229669-9670 Latin Drive: Brazil Spends Millions to Put Alcohol in Cars and Save Oil
- 1000229671 Can US Reduce Imports with Gasoline? Some Say Yes, But Officials Are Dubious
- 1000229672-9673 Bacterial Insulin Production Hears Reality
- 1000229674 Business World
- 1000229675-9677 Who Should Play God?
- 1000229678 Schering Plough New York Analysts' Meeting December 7, 1977
- 1000229679 Indiana Standard Labels Purchase Offer Part of Move to Wider Technology Base
- 1000229680 Big Deal for Berkley Bugs
- 1000229681 Oil-Less World May Run on Bugs
- 1000229682-9685 Tinkering with Life
- 1000229686-9687 Set for Biology's New Revolution
- 1000229688 Little Black Box of Cetus
- 1000229689-9695 Industry Is Finding More Jobs for Microbes
- 1000229696-9701 Dup of Id 1000229657-9661
- 1000229702-9710 Recombinant Molecular Research at Cetus Corporation
- 1000229711-9715 New Cetus Antibiotic
- 1000229716-9720 Letter to the Shareholders
- 1000229721-9726 Letter to Shareholders
- 1000229727-9728 Letters to the Shareholders
- 1000229729-9730
- 1000229731-9734 Letter to the Shareholders
- 1000229735-9736 Letter to Shareholders
- 1000229737-9749 the Manipulation of Genes
- 1000229750-9770 Microbial Genetics and the Future of the Pharmaceutical Industry
- 1000229771-9774 Recombinant Dna: Fact and Fiction
- 1000229775-9778 Testomony of Ronald E Cape, Phd President, Cetus Corporation, Berkeley, California Before the House Subcommittee on Science, Research and Technology
- 1000229779-9797 Biosystems Poised for Growth
- 1000229798-9805 Testimony of Ronald E. Cape, Ph.D President, Cetus Corporation, Berkley, California Before the Senate Subcommittee on Science, Technology and Space
- 1000229806-9807 Statement of Ronald E. Cape, Ph.D President, Cetus Corporation, Berkeley, California Before A Special Joint Congressional Hearing in Conjunction with Oversight Hearings on Science and Technology Policy the Senate Subcommittee on Science, Technology and Space of the Commerce, Science and Transportation Committee Presiding, Senator Adlai Stevenson, III Washington, Dc
- 1000229808-9811 Statement of Ronald E. Cape, Ph.D. President, Cetus Corporation, Berkeley, California at the Annual Meeting of the American Association for the Advancement of Science Session on Recombinant Dna Public Health and Biomedical Research Policy Washington, D.C.
- Characteristic
- CONF, CONFIDENTIAL
- Litigation
- Stmn/Produced
- Request
- Stmn/R1-004
- Stmn/R1-150
- Named Person
- Narang, S.A.
- Area
- WAKEHAM,HELMUT/KAROL SHARPE'S OFFICE
- Named Organization
- Board of Scientific Advisors
- Cetus
- Date Loaded
- 05 Jun 1998
- UCSF Legacy ID
- yfo74e00
Document Images
WA
1
;~.ir;r~.f:
+i.i

Patents
Cetus Corporation is active in obtaining-patent protection for its
significance. In many of these cases, discretion precludes specific
binant DNA discoveries, and specific processes of definite industrial
developments, where appropriate. Coverage is expected in a wide number
of technological areas, including cloning techniques, fusion and recom-
description
~ J
'
.
a,.;,) ... .
e~
.
.
, In the area of recombinant DNA there has been much recent discussion of
dictates dealing with particular companies.
implying that involvement in the commercialization of this technology
the confused patent scene. Many outlandish assertions are being made,
actively challenge the validity of certain patents,`if issued, when it -
Cetus Corporation firmly believes such claims to be",ridiculous, and will
private profit. Jc~ ` o~ O4~
certain arrangements in which public funds were`used as leverage for
seems appropriate to do so. We may also challenge;the legitimacy of
mental technology without which~there couid not have been accomplished
of one of its employees and his co=w'orkers,.who developed the funda-
More to the point, Cetus has applied.for 'patent protection on the work
and by the Gilbert group of rat insuliri.
the successful expression in bacteria by the Boyer group of somatostatin,
laboratory in~the world, will probably be even more important in the
long run.
G ZY ,~
a,©.,~{,~ a~~. .
.c,~., ~a ~w .. . . .
which, to our knowledge, we are building more quickly than any private
capability, reflected in'facilities, know-how, and in-house skills,
believe we have a broadly-based technological lead, and intend to main-
tain it. Patents will_be part of the picture, but only part. Overall
:
There is much excitement ahead, and many new discoveries waiting to be
made. A number ofthemwill_'doubtless be patented, some by Cetus. We
presently carrying this~work forward in Cetus laboratories).
V
Further, the patent for the'chemicalymethods used by the Boyer group to
construct synthetic geneslis held-by Dr. Saran A. Narang, a member of
the Cetus Board of Scientific Advisors, and co-workers (one of whom is

t.-, .....
; _. . . > ~ , s3 `, ;~O'. ; . ^ ¢'; .
'0 t'~.%
0 4a
7
3~0
t..,-
.
5f T ~
_ ..-.
~J T ~ y
~
^.r.'~~~ R- ~i'..t`~~ ~r I$~~ ki-t~ ~r5
t"..'t ~v -
.r,Y' ...r ~' . . ~ t: `~;~..~'E`: ~~ .7~ '3 ~'`,J~' . ~~''_5~... _
J.`{.C, .,41; a 1iil R!ifl:114
:
~. 1v~z~ r{ia~r a: '~it F~;C~ ,;%i Yf.s1.v ~:.: .:al:
K4 y. +h 1
._.. l1 ~,µiY Y Y w
3 ./ w~ ~ 5~~~ ~'.
V O '11 +
~ r ~. . ro.p4'{ a i;~ :vi
.
oc~{~
.. ~.. ,..
^. O~
y
¢r
G
G
o
G G~~~~
O
0
G
O
4e Aofi~
y.T
.,.
v.A:.J
